Background Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination
recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in …

Malaria persists as an undiminished global problem, but the resources available to address
it have increased. Many tools for understanding its biology and epidemiology are well …

Plasmodium falciparum resistance to atovaquone-proguanil has so far been associated with
Y268S or Y268N mutations in cytochrome b, although these changes were identified in only …

The development of new antimalarials is required because of the threat of resistance to
current antimalarial therapies. To discover new antimalarial chemotypes, we screened the …

Résumé Au cours de leur évolution, les micro-organismes ont su déjouer les pièges qui leur
sont tendus par l'environnement et notamment leur hôte (immunité et utilisation de …

The usefulness of atovaquone-proguanil (AP) as an antimalarial treatment is compromised
by the emergence of atovaquone resistance during therapy. However, the origin of the …

We determined the level of in vitro resistance of Plasmodium falciparum parasites to
standard antimalarial drugs, such as chloroquine, quinine, amodiaquine, halofantrine …

Malaria control is threatened by a limited pipeline of effective pharmaceuticals against drug-
resistant strains of Plasmodium falciparum. Components of the mitochondrial electron …

Background Artemisinin-based combination therapies (ACTs) are recommended for the
treatment of acute uncomplicated falciparum malaria in many malaria-endemic countries …

Background Based on report of declining efficacy of chloroquine, Ghana shifted to the use of
artemisinin-based combination therapy (ACT) in 2005 as the first-line anti-malarial drug …